Biofrontera Current Liabilities

What does Biofrontera do? Biofrontera Inc generates revenue through the commercialization of pharmaceutical products for dermatological conditions. The company's primary product Ameluz, a prescription drug used with the BF-RhodoLED lamp series for photodynamic therapy, treats actinic keratoses on the face and scalp. Ameluz is sold in the United States for lesion-directed and field-directed treatment of mild-to-moderate actinic keratoses. The company also markets Xepi, a topical antibiotic for impetigo treatment in adults and children two months and older, targeting bacterial skin infections caused by Staphylococcus aureus or Streptococcus pyogenes. Both products are licensed and sold directly to healthcare providers and pharmacies. Biofrontera's revenue streams come from the sale of Ameluz and Xepi to U.S. healthcare providers and pharmacies. The company focuses on dermatological treatments, specifically addressing actinic keratoses and impetigo. Ameluz is used in combination with the BF-RhodoLED lamp series, creating a bundled solution for photodynamic therapy. Xepi serves as a standalone topical antibiotic for impetigo, a common skin infection. The company's target customers include dermatologists and pediatricians who treat skin conditions in adult and pediatric patients. The company's business model centers on licensed pharmaceutical products, with Ameluz and Xepi as its core offerings. Ameluz is used for photodynamic therapy of actinic keratoses, while Xepi targets impetigo infections. Both products are prescribed in the United States for specific dermatological conditions, with Ameluz requiring the BF-RhodoLED lamp series for full treatment. The company's revenue is derived from direct sales of these products to healthcare providers and pharmacies, focusing on the U.S. market for dermatological treatments. Biofrontera is one of the most popular companies on Eulerpool.